S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Laser breakthrough could send stock soaring 2,467% (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:NVCR

NovoCure (NVCR) Stock Forecast, Price & News

$17.35
-0.24 (-1.36%)
(As of 09/22/2023 ET)
Compare
Today's Range
$17.25
$17.78
50-Day Range
$17.35
$40.57
52-Week Range
$17.14
$120.03
Volume
1.04 million shs
Average Volume
2.75 million shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.38

NovoCure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
201.9% Upside
$52.38 Price Target
Short Interest
Bearish
9.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
1.07mentions of NovoCure in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$31,639 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.07) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

154th out of 963 stocks

Surgical & Medical Instruments Industry

23rd out of 97 stocks


NVCR stock logo

About NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Price History

NVCR Stock News Headlines

3M, Boston Scientific rise; Abcam, NovoCure fall, Monday, 8/28/2023
Stocks that are trading heavily or have substantial price changes on Monday: 3M, Boston Scientific rise; Abcam, NovoCure fall
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Should You Hold NovoCure Limited (NVCR)?
Down 31% in 1 Day, What's Next for NovoCure Stock?
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Why Novocure Stock Fell 24.4% This Week
What 11 Analyst Ratings Have To Say About NovoCure
What's Going On With NovoCure Stock Today?
Why Is Novocure (NVCR) Stock Down 30% Today?
Could NovoCure Stock Help You Become a Millionaire?
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Company Calendar

Last Earnings
7/27/2023
Today
9/24/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,320
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.38
High Stock Price Forecast
$102.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+201.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-92,530,000.00
Pretax Margin
-31.71%

Debt

Sales & Book Value

Annual Sales
$537.84 million
Book Value
$4.20 per share

Miscellaneous

Free Float
100,571,000
Market Cap
$1.85 billion
Optionable
Optionable
Beta
0.62
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. William F. DoyleMr. William F. Doyle (Age 61)
    Exec. Chairman
    Comp: $1.52M
  • Mr. Asaf DanzigerMr. Asaf Danziger (Age 57)
    Pres, CEO & Director
    Comp: $1.7M
  • Ms. Ashley CordovaMs. Ashley Cordova (Age 43)
    Chief Financial Officer
    Comp: $933.39k
  • Mr. Wilhelmus C. M. GroenhuysenMr. Wilhelmus C. M. Groenhuysen (Age 65)
    Chief Operating Officer
    Comp: $1.01M
  • Mr. Pritesh ShahMr. Pritesh Shah (Age 44)
    Chief Growth Officer
    Comp: $810.6k
  • Mr. Frank LeonardMr. Frank Leonard
    Pres of CNS Cancers U.S.
  • Prof. Yoram Palti M.D. (Age 85)
    Ph.D., Founder & CTO
  • Dr. Moshe Giladi Ph.D.
    Chief Science Officer
  • Ms. Ingrid Goldberg
    VP of Investor Relations
  • Mr. Barak Ben Arye (Age 47)
    Gen. Counsel













NVCR Stock - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price forecast for 2023?

9 brokers have issued 1 year price targets for NovoCure's shares. Their NVCR share price forecasts range from $25.00 to $102.00. On average, they expect the company's stock price to reach $52.38 in the next twelve months. This suggests a possible upside of 201.9% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2023?

NovoCure's stock was trading at $73.35 at the beginning of the year. Since then, NVCR shares have decreased by 76.3% and is now trading at $17.35.
View the best growth stocks for 2023 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, July, 27th. The medical equipment provider reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.04. The medical equipment provider earned $126.05 million during the quarter, compared to the consensus estimate of $124.25 million. NovoCure had a negative net margin of 34.35% and a negative trailing twelve-month return on equity of 40.21%. The business's revenue was down 10.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.23) EPS.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital World Investors (10.68%), Capital International Investors (8.26%), Baillie Gifford & Co. (8.18%), BlackRock Inc. (7.62%), Geode Capital Management LLC (1.37%) and Credit Suisse AG (0.77%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $17.35.

How much money does NovoCure make?

NovoCure (NASDAQ:NVCR) has a market capitalization of $1.85 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does NovoCure have?

The company employs 1,320 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.

This page (NASDAQ:NVCR) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -